LACOSAMIDE
|
- $49 - $278
- Product name: LACOSAMIDE
- CAS: 175481-36-4
- MF: C13H18N2O3
- MW: 250.29
- EINECS:605-756-0
- MDL Number:MFCD08272557
- Synonyms:LACOSAMIDE;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Harkoseride;SPM 927;(2R)-N-benzyl-2-acetaMido-3-MethoxypropanaMide;LacosaMide (1.0Mg/ML in Acetonitrile);(R)-2-Acetamido-N-benzyl-3-methoxypropionamide
8 prices
Selected condition：
Brand
- Biosynth Carbosynth
- Cayman Chemical
- DC Chemicals
- Sigma-Aldrich
Package
- 5mg
- 10mg
- 25mg
- 50mg
- 100mg
- 1mL
- ManufacturerBiosynth Carbosynth
- Product numberBL164605
- Product descriptionLacosamide
- Packaging10mg
- Price$68
- Updated2021-12-16
- Buy
- ManufacturerBiosynth Carbosynth
- Product numberBL164605
- Product descriptionLacosamide
- Packaging50mg
- Price$175
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number10012592
- Product descriptionLacosamide ≥98%
- Packaging5mg
- Price$49
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number10012592
- Product descriptionLacosamide ≥98%
- Packaging10mg
- Price$87
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number10012592
- Product descriptionLacosamide ≥98%
- Packaging25mg
- Price$152
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number10012592
- Product descriptionLacosamide ≥98%
- Packaging50mg
- Price$278
- Updated2024-03-01
- Buy
- ManufacturerDC Chemicals
- Product numberDC8797
- Product descriptionLacosamide >98%
- Packaging100mg
- Price$200
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product numberL-029
- Product descriptionLacosamide solution 1.0?mg/mL in acetonitrile, ampule of 1?mL, certified reference material, Cerilliant?
- Packaging1mL
- Price$202
- Updated2024-03-01
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Biosynth Carbosynth | BL164605 | Lacosamide | 10mg | $68 | 2021-12-16 | Buy |
| Biosynth Carbosynth | BL164605 | Lacosamide | 50mg | $175 | 2021-12-16 | Buy |
| Cayman Chemical | 10012592 | Lacosamide ≥98% | 5mg | $49 | 2024-03-01 | Buy |
| Cayman Chemical | 10012592 | Lacosamide ≥98% | 10mg | $87 | 2024-03-01 | Buy |
| Cayman Chemical | 10012592 | Lacosamide ≥98% | 25mg | $152 | 2024-03-01 | Buy |
| Cayman Chemical | 10012592 | Lacosamide ≥98% | 50mg | $278 | 2024-03-01 | Buy |
| DC Chemicals | DC8797 | Lacosamide >98% | 100mg | $200 | 2021-12-16 | Buy |
| Sigma-Aldrich | L-029 | Lacosamide solution 1.0?mg/mL in acetonitrile, ampule of 1?mL, certified reference material, Cerilliant? | 1mL | $202 | 2024-03-01 | Buy |
Properties
Melting point :141-143?C
alpha :D23 +16.0° (c = 1 in CH3OH)
Boiling point :536.4±50.0 °C(Predicted)
Density :1.120±0.06 g/cm3(Predicted)
Flash point :2℃
storage temp. :Refrigerator
solubility :DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml
form :A crystalline solid
pka :14.19±0.46(Predicted)
InChIKey :VPPJLAIAVCUEMN-GFCCVEGCSA-N
CAS DataBase Reference :175481-36-4
alpha :D23 +16.0° (c = 1 in CH3OH)
Boiling point :536.4±50.0 °C(Predicted)
Density :1.120±0.06 g/cm3(Predicted)
Flash point :2℃
storage temp. :Refrigerator
solubility :DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml
form :A crystalline solid
pka :14.19±0.46(Predicted)
InChIKey :VPPJLAIAVCUEMN-GFCCVEGCSA-N
CAS DataBase Reference :175481-36-4
Safety Information
| Symbol(GHS): |
 
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Danger | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|
Description
Lacosamide (LCM), (SPM 927, (R)-2-acetamido-N-benzyl-3-methoxypropionamide, previously referred to as harkoseride or ADD 234037) is a member of a series of functionalized amino acids that were specifically synthesized as anticonvulsant or antiepileptic drug. It reduces the spread of seizure activity in the brain. Lacosamide appears to have a dual mode of action: selective enhancement of sodium channel inactivation and modulation of collapsin response mediator protein-2. Compared to novel antiepileptic drugs, lacosamide has broader and higher efficacy, better tolerability, and improved pharmacokinetic properties. Lacosamide is in phase III clinical development for adjunctive treatment of patients with uncontrolled partial-onset seizures, and for monotherapy of patients with painful diabetic neuropathy. It is absorbed rapidly and completely after oral administration. Lacosamide has an elimination half-life of approximately 13 hours and a low potential for drug interactions. Additionally, lacosamide exhibits linear, dose-proportional pharmacokinetics with low intra- and interpatient variability.Related product price
- Febuxostat
$5-5690 - 2-(Acetylamino)-N-(phenylmethyl)-2-propenamide
$185-2085 - Benzylamine hydrochloride
$14-1680
Suppliers and manufacturers
Capot Chemical Co.,Ltd.
Nanjing Gold Pharmaceutical Technology Co. Ltd.
Henan Tianfu Chemical Co.,Ltd.
Hangzhou FandaChem Co.,Ltd.
Shanghai Yingrui Biopharma Co., Ltd.
ATK CHEMICAL COMPANY LIMITED
